MA-BATTERY-VENTURES
26.3.2024 12:01:26 CET | Business Wire | Press release
Battery Ventures, a global, technology-focused investment firm, today announced a significant investment in Mobius Institute (“Mobius”), a company that specializes in reliability improvement, conditioning-monitoring, and precision-maintenance training and certification.
Mobius delivers its training via public, in-plant, and online training programs and has trained more than 70,000 professionals from 180 countries since 2005. In addition to training, a related entity to the company, Mobius Institute Board of Certification, is an ISO/IEC 17024 and ISO 18436-accredited certification body that provides globally recognized certification to reliability professionals, vibration analysts, ultrasound analysts, thermal imaging, and lubrication specialists worldwide.
Mobius Institute is seen as an authority in the industrial asset-reliability space, which is growing in importance as companies transition to predictive and data-based maintenance regimes to operate more efficiently and meet new sustainability targets. Via its network of training partners, Mobius has trained maintenance and reliability professionals across a wide range of industries with students from Pfizer, Rio Tinto, Abbott, Abbvie, Ford, Coca-Cola, Samsung, ABB, Cargill, Nestle, Siemens, Dow, Amazon, Bayer, Mercedes-Benz, NASA, and Hyundai, among others.
Jason Tranter, the co-founder of Mobius, said he hoped the partnership with Battery will help his company scale to a new level. “My wife, Georgie, and I started the business in our house in 1999 with the goal of making vibration analysis and condition monitoring understandable. We never imagined Mobius Institute growing to this scale with almost 10,000 students trained last year alone,” he said. “Having developed a relationship with Battery over the past several years, I am excited to see Mobius continue to grow under Battery’s ownership as the starting point of a new platform.”
As part of the transaction, Tranter will serve as a technical advisor to Mobius.
Battery’s goal with the transaction is to create a large, innovative, asset-reliability and industrial-services player; the firm expects to build upon Mobius’ strength in asset reliability while expanding the portfolio into the broader market for industrial training, certification, and specialized products & services.
As part of this initiative, Marcus Pillion joins the company as Group CEO to drive M&A and continued organic growth, as well as to oversee integration efforts. Pillion joins Mobius after serving most recently as the CEO of Des-Case before its acquisition by Timken (NYSE: TKR) in 2023. Prior to Des-Case, Pillion had previous executive experience across several asset-reliability and condition-monitoring businesses including TRITEC Performance Solutions, Colfax Fluid Handling, EagleBurgmann, SKF and John Crane.
“I am excited to join forces with Battery, a seasoned industrial-technology investor with extensive experience creating platforms through global M&A,” said Pillion. “Having used Mobius Institute training across all of the companies I previously worked for, I am excited to build upon the global brand Mobius has created as we enter into the next phase of its growth trajectory.”
“We are thrilled to partner with Mobius and its exceptional staff as we pursue the next phase of growth for the business,” said Zack Smotherman, a Battery general partner. “Having followed the asset-reliability and condition-monitoring market for many years, we’ve observed an accelerating trend in predictive maintenance and believe we are still in the early innings of this movement as many industries increasingly adopt these solutions.”
Added Battery Principal Justin Rosner: “We are grateful to Jason for the opportunity to partner with Mobius and excited about the journey ahead as we look to leverage Mobius’s global reputation to improve asset reliability across many industries in the years to come.”
About Mobius Institute
Mobius Institute is a worldwide provider of reliability improvement, condition monitoring, and precision maintenance education to industrial plant managers, reliability engineers, and condition monitoring specialists, allowing plants to be successful in implementing reliability improvement and condition monitoring programs. Mobius delivers its training via public, in-person / onsite, and online education programs with a key advantage being its unique training style that uses innovative 3D animations and software simulations, making complex topics easier to understand. Mobius has trained and certified more than 70,000 industrial professionals from 180 countries since 2005 with thousands more engaged through distance learning programs and Mobius’ online community MOBIUS CONNECT. Learn more at https://www.mobiusinstitute.com/about-mobius-institute/.
About Battery
Battery partners with exceptional founders and management teams developing category-defining businesses in markets including software and services, enterprise infrastructure, consumer tech, healthcare IT and industrial technology and life-science tools. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from offices in Boston, San Francisco, Menlo Park, New York, London, and Tel Aviv. Follow the firm on X @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240326724392/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom